Guideline Updates G18: IDSA 2025 Complicated UTI Guideline: New Clinical Definitions and Empiric Therapy

The 2025 IDSA update defines complicated UTI by clinical findings rather than risk factors alone, retires fluoroquinolones as empiric therapy, and favors carbapenems over piperacillin-tazobactam for ESBL disease